Date: 2014-05-15
Type of information: Development agreement
Compound: molecular diagnostic technology for infectious disease pathogens utilising Enigma’s proprietary chemistries and the Enigma® Mini Laboratory system (“Enigma ML”)
Company: Enigma Diagnostic (UK) National Institute for Communicable Disease Control and Prevention, China Center for Disease Control and Prevention (China)
Therapeutic area: Diagnostic - Infectious diseases
Type agreement: development
Action mechanism:
Disease:
Details: * On May 15, 2014, Enigma Diagnostics, a global leader in molecular diagnostic point-of-care (PoC) infectious disease testing, announced a collaboration agreement with China’s National Institute for Communicable Disease Control and Prevention, China Center for Disease Control and Prevention (“ICDC”). Under the terms of the agreement Enigma and ICDC will collaborate in the development of rapid and convenient molecular diagnostic technology for infectious disease pathogens utilising Enigma’s proprietary chemistries and the Enigma® Mini Laboratory system (“Enigma ML”). The Enigma ML’s highly accurate and multiplex assay reporting capabilities enables testing for the widest range of DNA and RNA disease targets with a fast turnaround time. The unique features of the system offer a hybrid laboratory and stand-alone diagnostic testing platform, designed to be of use in developed and emerging healthcare programmes. Easy to use, with on-board data handling and networking capability enabling multiple data sharing routes, the fully automated system requires simple training and has shown nil operator variance in recent trials. The Enigma ML provides a major advantage in laboratories or diverse testing locations where testing is undertaken by several different operators. The Enigma ML provides countries with rapidly expanding healthcare systems the opportunity to build a diagnostic architecture which is cost-effective and patient-centric across multiple testing sites, unconstrained by traditional laboratory costs and limited physician availability. The data handling and routing capabilities allow physicians access to patient data securely and remotely, ensuring fast and accurate diagnosis with immediate and relevant treatment for patients.
Financial terms:
Latest news:
